Get the Stockscreener App
17.97
0.17%
+0.03
After Hours:
18.00
0.03
+0.17%
Harrow Inc stock is currently priced at $17.97, with a 24-hour trading volume of 393.02K.
It has seen a +0.17% increased in the last 24 hours and a +10.65% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $18.23 pivot point. If it approaches the $17.53 support level, significant changes may occur.
Previous Close:
$17.94
Open:
$17.8
24h Volume:
393.02K
Market Cap:
$635.81M
Revenue:
$130.19M
Net Income/Loss:
$-24.41M
P/E Ratio:
-32.09
EPS:
-0.56
Net Cash Flow:
$-148.71M
1W Performance:
-1.10%
1M Performance:
+10.65%
6M Performance:
+81.88%
1Y Performance:
-7.85%
1D Range:
$17.02
$18.21
52W Range:
$7.60
$22.63
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
858-704-4040
Address
12264 El Camino Real, Suite 350, San Diego, CA
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
Harrow Inc Stock (HROW) Latest News
Braidwell LP Has $16.78 Million Stock Position in Harrow, Inc. (NASDAQ:HROW) - MarketBeat
MarketBeat
Harrow, Inc. (NASDAQ:HROW) Shares Sold by Wasatch Advisors LP - Defense World
Defense World
TD Asset Management Inc Raises Stake in Genworth Financial, Inc. (NYSE:GNW) - Defense World
Defense World
Steward Partners Investment Advisory LLC Purchases 157 Shares of Leidos Holdings, Inc. (NYSE:LDOS) - Defense World
Defense World
Stifel Financial Corp Buys 91,881 Shares of Harrow, Inc. (NASDAQ:HROW) - MarketBeat
MarketBeat
TD Asset Management Inc Sells 11200 Shares of Southside Bancshares, Inc. (NASDAQ:SBSI) - Defense World
Defense World
Harrow Inc Stock (HROW) Financials Data
Harrow Inc (HROW) Revenue 2024
HROW reported a revenue (TTM) of $130.19 million for the quarter ending December 31, 2023, a +46.95% rise year-over-year.
Harrow Inc (HROW) Net Income 2024
HROW net income (TTM) was -$24.41 million for the quarter ending December 31, 2023, a -73.30% decrease year-over-year.
Harrow Inc (HROW) Cash Flow 2024
HROW recorded a free cash flow (TTM) of -$148.71 million for the quarter ending December 31, 2023, a -2,351% decrease year-over-year.
Harrow Inc (HROW) Earnings per Share 2024
HROW earnings per share (TTM) was -$0.76 for the quarter ending December 31, 2023, a -46.15% decline year-over-year.
About Harrow Inc
Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
0.94%
Cap:
|
Volume (24h):